Could a common arthritis drug tame recurring eye inflammation?
NCT ID NCT03020992
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether certolizumab pegol (Cimzia), a drug already used for arthritis, can reduce flares of anterior uveitis—a painful eye inflammation—in people with axial spondyloarthritis who have had uveitis before. About 89 adults with active axial spondyloarthritis and a history of uveitis will receive the drug and be monitored for new eye inflammation episodes over 48 weeks. The goal is to see if the drug can prevent or reduce these flares.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
certolizumab pegol (Cimzia)
What this could lead to
If it works, this could offer a way to reduce painful eye inflammation flares in people with axial spondyloarthritis.
What could go wrong
This is a small, open-label study without a placebo group, so results may be less reliable. The drug may not work for everyone and carries risks like infection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AXIAL SPONDYLOARTHRITIS (AXSPA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
As0007 101
Brno, Czechia
-
As0007 102
Prague, Czechia
-
As0007 103
Brno, Czechia
-
As0007 105
Prague, Czechia
-
As0007 107
Brno, Czechia
-
As0007 108
Ostrava, Czechia
-
As0007 109
Pardubice, Czechia
-
As0007 301
Freiburg im Breisgau, Germany
-
As0007 302
München, Germany
-
As0007 303
Münster, Germany
-
As0007 401
Amsterdam, Netherlands
-
As0007 501
Warsaw, Poland
-
As0007 502
Torun, Poland
-
As0007 504
Wroclaw, Poland
-
As0007 505
Warsaw, Poland
-
As0007 506
Bialystok, Poland
-
As0007 507
Wroclaw, Poland
-
As0007 508
Wroclaw, Poland
-
As0007 509
Poznan, Poland
-
As0007 510
Lublin, Poland
-
As0007 511
Poznan, Poland
-
As0007 601
Córdoba, Spain
-
As0007 604
Barcelona, Spain